Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials

References

• Handelsman Y Bloomgarden ZT Grunberger G American association of clinical endocrinologists and American college of endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015 Endocr Pract 2015 21 Suppl 1 1 87 25869408
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes, 2015 – a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2015 38 1 140 149 25538310
   PubMed Web of Science ®Google Scholar
• Canadian Diabetes Association Clinical Practice Guidelines Expert C Imran SA Rabasa-Lhoret R Ross S Targets for glycemic control Can J Diabetes 2013 37 Suppl 1 S31 S34 24070959
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation, Clinical Guidelines Task Force Global guideline for type 2 diabetes Available from http://www.idf.org/guideline-type-2-diabete Accessed October 2015
   Google Scholar
• Internal Clinical Guidelines Team, National Institute for Health and Care Excellence Clinical guideline update. Type 2 diabetes in adults: management Available from http://www.nice.org.uk/guidance/indevel-opment/gid-cgwave0612/documents Accessed October 2015
   Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2016 executive summary Endocr Pract 2016 22 1 84 113 26731084
   PubMed Web of Science ®Google Scholar
• Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 9548 1696 1705 17098089
   PubMed Web of Science ®Google Scholar
• Bucher HC Guyatt GH Griffith LE Walter SD The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 1997 50 6 683 691 9250266
   PubMed Web of Science ®Google Scholar
• Glenny AM Altman DG Song F Indirect comparisons of competing interventions Health Technol Assess 2005 9 26 1 134 iii iv
   PubMed Web of Science ®Google Scholar
• Caldwell DM Ades AE Higgins JP Simultaneous comparison of multiple treatments: combining direct and indirect evidence BMJ 2005 331 7521 897 900 16223826
   PubMed Web of Science ®Google Scholar
• Sutton A Ades AE Cooper N Abrams K Use of indirect and mixed treatment comparisons for technology assessment Pharmacoeconomics 2008 26 9 753 767 18767896
   PubMed Web of Science ®Google Scholar
• Lu G Ades AE Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 2004 23 20 3105 3124 15449338
   PubMed Web of Science ®Google Scholar
• Aroda VR Henry RR Han J Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review Clin Ther 2012 34 6 1247 1258.e22 22608780
   PubMed Web of Science ®Google Scholar
• Scott DA Boye KS Timlin L Clark JF Best JH A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo Diabetes Obes Metab 2013 15 3 213 223 22958381
   PubMed Web of Science ®Google Scholar
• Eng C Kramer CK Zinman B Retnakaran R Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis Lancet 2014 384 9961 2228 2234 25220191
   PubMed Web of Science ®Google Scholar
• Karagiannis T Liakos A Bekiari E Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials Diabetes Obes Metab 2015 17 11 1065 1074 26395850
   PubMed Web of Science ®Google Scholar
• Liu FP Dong JJ Yang Q Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: a systematic review and meta-analysis J Diabetes 2015 7 3 322 328 25047138
   PubMed Web of Science ®Google Scholar
• Sun F Chai S Yu K Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis Diabetes Technol Ther 2015 17 1 35 42 25375397
   PubMed Web of Science ®Google Scholar
• Zaccardi F Htike ZZ Webb DR Khunti K Davies MJ Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis Ann Intern Med 2016 164 2 102 113 26642233
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [homepage on the Internet] Available from: https://clinicaltrials.gov Accessed April 15, 2015
   Google Scholar
• Dias S Welton NJ Sutton AJ Ades AE NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials Sheffield Decision Support Unit 2011
   Google Scholar
• Ades AE Sculpher M Sutton A Bayesian methods for evidence synthesis in cost-effectiveness analysis Pharmacoeconomics 2006 24 1 1 19
   PubMed Web of Science ®Google Scholar
• Sutton A Ades AE Cooper N Abrams K Use of indirect and mixed treatment comparisons for technology assessment Pharmacoeconomics 2008 26 9 753 767 18767896
   PubMed Web of Science ®Google Scholar
• Sutton AJ Abrams KR Bayesian methods in meta-analysis and evidence synthesis Stat Methods Med Res 2001 10 4 277 303 11491414
   PubMed Web of Science ®Google Scholar
• MRC Biostatistics Unit The BUGS project Available from: http://www.mrc-bsu.cam.ac.uk/bugs Accessed August 19, 2016
   Google Scholar
• Lunn D Jackson C Best N Thomas A Spiegelhalter D The BUGS Book: A Practical Introduction to Bayesian Analysis London CRC Press 2013
   Google Scholar
• MRC Biostatistics Unit DIC: deviance information criterion Available from: http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/dicpage.shtml#q15 Accessed August 19, 2016
   Google Scholar
• DerSimonian R Laird N Meta-analysis in clinical trials Control Clin Trials 1986 7 3 177 188 3802833
   PubMedGoogle Scholar
• Fleiss JL The statistical basis of meta-analysis Stat Methods Med Res 1993 2 2 121 145 8261254
   PubMedGoogle Scholar
• Borenstein M Hedges LV Higgins JP Rothstein HR Introduction to Meta-analysis Chichester, UK Wiley & Sons 2009
   Google Scholar
• Dias S Sutton AJ Welton NJ Ades AE NICE DSU Technical Support Document 3 – Heterogeneity: Subgroups, Meta-regression, Bias and Bias-Adjustment Sheffield Decision Support Unit 2011
   Google Scholar
• DeFronzo RA Stonehouse AH Han J Wintle ME Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials Diabet Med 2010 27 3 309 317 20536494
   PubMed Web of Science ®Google Scholar
• StataCorp LP Stata/MP 14.0 for Windows [software] Available from: www.stata.com/statamp Accessed August 19, 2016
   Google Scholar
• Harris RJ Bradburn MJ Deeks JJ Harbord RM Altman DG Sterne JA Metan: fixed- and random-effects meta-analysis Stata J 2008 8 1 3 28
   Web of Science ®Google Scholar
• Reusch J Stewart MW Perkins CM Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin Diabetes Obes Metab 2014 16 12 1257 1264 25155146
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Safety and efficacy study of albiglutide in type 2 diabetes Available from: https://clinicaltrials.gov/ct2/show/NCT00849017. NLM identifier: NCT00849017 Accessed August 19, 2016
   Google Scholar
• Ahren B Johnson SL Stewart M HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin Diabetes Care 2014 37 8 2141 2148 24898304
   PubMed Web of Science ®Google Scholar
• Weissman PN Carr MC Ye J HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea Diabetologia 2014 57 12 2475 2484 25208756
   PubMed Web of Science ®Google Scholar
• Home PD Shamanna P Stewart M Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5 Diabetes Obes Metab 2015 17 2 179 187 25406730
   PubMed Web of Science ®Google Scholar
• Rosenstock J Fonseca VA Gross JL Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro Diabetes Care 2014 37 8 2317 2325 24898300
   PubMed Web of Science ®Google Scholar
• Pratley RE Nauck MA Barnett AH Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study Lancet Diabetes Endocrinol 2014 2 4 289 297 24703047
   PubMed Web of Science ®Google Scholar
• Wysham C Blevins T Arakaki R Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Diabetes Care 2014 37 8 2159 2167 24879836
   PubMed Web of Science ®Google Scholar
• Giorgino F Benroubi M Sun JH Zimmermann AG Pechtner V Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2) Diabetes Care 2015 38 12 2241 2249 26089386
   PubMed Web of Science ®Google Scholar
• Umpierrez G Povedano ST Manghi FP Shurzinske L Pechtner V Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) Diabetes Care 2014 37 8 2168 2176 24842985
   PubMed Web of Science ®Google Scholar
• Blonde L Jendle J Gross J Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study Lancet 2015 385 9982 2057 2066 26009229
   PubMed Web of Science ®Google Scholar
• Nauck M Weinstock RS Umpierrez GE Guerci B Skrivanek Z Milicevic Z Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) Diabetes Care 2014 37 8 2149 2158 24742660
   PubMed Web of Science ®Google Scholar
• Dungan KM Povedano ST Forst T Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial Lancet 2014 384 9951 1349 1357 25018121
   PubMed Web of Science ®Google Scholar
• Buse JB Henry RR Han J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004 27 11 2628 2635 15504997
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Ratner RE Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 5 1092 1100 15855572
   PubMed Web of Science ®Google Scholar
• Kendall DM Riddle MC Rosenstock J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 5 1083 1091 15855571
   PubMed Web of Science ®Google Scholar
• Moretto TJ Milton DR Ridge TD Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 2008 30 8 1448 1460 18803987
   PubMed Web of Science ®Google Scholar
• Drucker DJ Buse JB Taylor K Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 2008 372 9645 1240 1250 18782641
   PubMed Web of Science ®Google Scholar
• Bergenstal RM Wysham C Macconell L Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 2010 376 9739 431 439 20580422
   PubMed Web of Science ®Google Scholar
• Diamant M Van Gaal L Stranks S Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Lancet 2010 375 9733 2234 2243 20609969
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Cuddihy RM Hanefeld M Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Diabetes Care 2012 35 2 252 258 22210563
   PubMed Web of Science ®Google Scholar
• Blevins T Pullman J Malloy J DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Metab 2011 96 5 1301 1310 21307137
   PubMed Web of Science ®Google Scholar
• Buse JB Nauck M Forst T Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 2013 381 9861 117 124 23141817
   PubMed Web of Science ®Google Scholar
• Marre M Shaw J Brändle M Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) Diabet Med 2009 26 3 268 278 19317822
   PubMed Web of Science ®Google Scholar
• Nauck M Frid A Hermansen K Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study Diabetes Care 2009 32 1 84 90 18931095
   PubMed Web of Science ®Google Scholar
• Garber A Henry R Ratner R Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 2009 373 9662 473 481 18819705
   PubMed Web of Science ®Google Scholar
• Zinman B Gerich J Buse JB Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) Diabetes Care 2009 32 7 1224 1230 19289857
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Vaag A Schmitz O Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 Met+SU): a randomised controlled trial Diabetologia 2009 52 10 2046 2055 19688338
   PubMed Web of Science ®Google Scholar
• Buse JB Rosenstock J Sesti G Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 2009 374 9683 39 47 19515413
   PubMed Web of Science ®Google Scholar
• Kahn SE Haffner SM Heise MA Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 2006 355 23 2427 2443 17145742
   PubMed Web of Science ®Google Scholar
• Nauck MA Del Prato S Meier JJ Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 2011 34 9 2015 2022 21816980
   PubMed Web of Science ®Google Scholar
• Nauck MA Meininger G Sheng D Terranella L Stein PP Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial Diabetes Obes Metab 2007 9 2 194 205 17300595
   PubMed Web of Science ®Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI AACE/ACE comprehensive diabetes management algorithm 2015 Endocr Pract 2015 21 4 438 447 25877012
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 2 diabetes – a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2009 32 1 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Stratton IM Adler AI Neil HA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 7258 405 412 10938048
   PubMed Web of Science ®Google Scholar
• Conn VS Ruppar TM Phillips LJ Chase JA Using meta-analyses for comparative effectiveness research Nurs Outlook 2012 60 4 182 190 22789450
   PubMed Web of Science ®Google Scholar
• Cipriani A Higgins JP Geddes JR Salanti G Conceptual and technical challenges in network meta-analysis Ann Intern Med 2013 159 2 130 137 23856683
   PubMed Web of Science ®Google Scholar
• Mills EJ Thorlund K Ioannidis JP Demystifying trial networks and network meta-analysis BMJ 2013 346 f2914 23674332
   PubMed Web of Science ®Google Scholar
• Jansen JP Fleurence R Devine B Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices – part 1 Value Health 2011 14 4 417 428 21669366
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Efficacy and safety of albiglutide in treatment of type 2 diabetes Available from: https://clinicaltrials.gov/ct2/show/results/NCT00838903. NLM identifier: NCT00838903 Accessed August 19, 2016
   Google Scholar